Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Menu
My View
  • Edit
  • Add your favourite topics for quick access
Meet the Team
Scrip Awards
Partnered Content
Scrip Asia 100
Report Store
Ask The Analyst
PItCH
PDF Library
RSS Feeds
Subscribe
Advertise
UsernamePublicRestriction
Tags:
Commercial Deals Outlook 2019

India Pharma In 2019: Buy, Build And Beware (Patient Power And Amazon)

  • Analysis

Executive Summary

2019 promises to be action-packed for Indian firms as they stay hungry for M&A and on course to transition to a more innovation-led play. But election year surprises in India, rising patient awareness, and the entry of non-traditional players like Amazon could well up the variable quotient for pharma, industry pundits tell Scrip.
Table

View full table

Advertisement

Related Content

Scrip
Deal Watch: Denali Partners With Sirion To Take On The Blood-Brain Barrier
Pink Sheet
New Window: India Extends Price Cap Exemption To Foreign Innovation
Scrip
Lupin Ends 2018 On High, Strikes Large MALT1 Deal With AbbVie
Scrip
Key Wins In US By Indian Firms - Keep An Eye On These In 2019
Medtech Insight
Texas Court Ruling Invalidating ACA Threatens Preexisting Illness Coverage, But It's Not The Final Word, Congress Says
In Vivo
Can Modicare Reshape India’s Health Care Paradigm?
Scrip
Big Statement By Aurobindo As It Seals $1bn Sandoz US Deal
Medtech Insight
Hips Don’t Lie: J&J Faces Compensation Maelstrom In India Over Faulty ASR Implants
Scrip
Amazon Hurricane Heading Towards Indian Pharma?

Topics

Related Companies

Advertisement
Tags:
Commercial Deals Outlook 2019
UsernamePublicRestriction

Register

SC124443

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By